DenovAI Biotech

DenovAI Biotech Overview

DenovAI is developing foundational technology platforms that can design proteins de novo - completely from scratch. The company is starting the journey to design next generation therapeutics like high-affinity antibodies, small protein and peptide biologics, and diagnostic reporters - all tailored to bind to their specific targets. Its AI-based platform for rapid de novo antibody discovery will design high-affinity binders to epitopes of choice, reduce the discovery process from months to days and broaden the scope of therapy to many more diseases. The platform for de novo protein design can design bespoke high-affinity binders for targets of choice – unlocking many applications in biologics and diagnostics.

Cumulative Funding Raised Over Time ($)

Latest News

Dec 18, 2023 · www.the-microbiologist.com

growth-positive

DenovAI uses artificial intelligence to discover therapeutic antibodies

Former EMBL staff scientist Kashif Sadiq has founded a start-up company, DenovAI Biotech, to develop an AI-powered biophysics solution for discovering potential antibodies and small protein biologics for therapeutic use. The company will use a computational approach to design proteins from scratch, potentially providing capabilities beyond pharmaceutical biologics, including diagnostics, enzyme and biomaterial design. DenovAI is the second startup formed by Israel-based AION Labs and is supported by investment from pharmaceutical companies Pfizer, AstraZeneca, Merck, and Teva, as well as the Israel Innovation Authority and the Israel Biotech Fund.

InvestmentPartners

Dec 14, 2023 · www.azorobotics.com

growth-positive

DenovAI Biotech Creates Designer Antibodies for Any Disease

DenovAI, a start-up founded by former EMBL scientist Kashif Sadiq, is developing an AI-powered biophysics solution to expedite and reduce costs in antibody discovery. The company aims to use advanced machine learning and computational biophysics to enhance the identification of antibodies crucial for the human immune systems defense against diseases. DenovAI represents the second venture launched by AION Labs and enjoys support from pharmaceutical entities such as Pfizer, AstraZeneca, Merck, and Teva, as well as Amazon Web Services, the Israel Innovation Authority, and the Israel Biotech Fund.

InvestmentPartners

Funding

Team Members

2

Employees: 11-50

Web & Social Links

Locations

4 Oppenheimer Building B 17th Floor, Rehovot, 7670104, Israel

Photos & Videos

No files yet

DenovAI Biotech Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info